In a recent study published in The Lancet Respiratory Medicine, researchers reported the TB-PRACTECAL clinical trial outcomes, which evaluated the efficacy and safety of oral bedaquiline, linezolid, and pretomanid (BPaL)-based regimens for pulmonary tuberculosis resistant to rifampicin.

After three years being held virtually due to the COVID-19 pandemic, the 2023 Union World Conference on Lung Health (Union Conference) took place in-person on 15-18 November 2023 in Paris, France under the theme 'Transforming evidence into practice'.

As yet another conference kicks off, it underscores the way such collaborations to end the infectious disease only serve to maintain the colonial status quo.

A combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, has the potential to become a 'universal TB regimen', shortening and improving treatment for both drug-sensitive and drug-resistant TB.

Two new clinical trials find first-ever safe and effective treatment to prevent multidrug-resistant TB in both children and adults.

endTB clinical trial offers multiple new shortened drug regimens to treat adults and children with multidrug–resistant TB.

Results of LIFT-TB operational research on BPaL regimen for treating drug-resistant TB in Central and Southeast Asia.

Preclinical results indicate robust antibody activity against tuberculosis and antimicrobial resistant virus strains; Data presented at The Union World Conference on Lung Health 2023

The roadmap outlines an ambitious five-year plan with 10 key actions to improve the prevention, treatment, and care of TB in children and adolescents.

This new resource lays out what activists need to know about the new drug-resistant TB treatment regimens, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.